Class Action Lawsuit Filed Against ESSA Pharma Inc.
Attorney Advertising—Bronstein, Gewirtz & Grossman, LLC, a law firm renowned for its work in investor protections, has informed shareholders that a class action lawsuit has been initiated against ESSA Pharma Inc. (NASDAQ: EPIX) and certain officers of the company. This legal move comes in response to substantial losses experienced by investors and seeks accountability for alleged violations of securities laws.
Understanding the Class Action
This lawsuit aims to recover damages for all individuals and entities who purchased or acquired ESSA securities during what is known as the Class Period. This period is crucial, stretching from December 12, 2023, to October 31, 2024, inclusive. All investors who fall within this time frame are encouraged to take action and join the lawsuit to protect their interests.
What are the Allegations?
The filed Complaint asserts that throughout the Class Period, ESSA and its officers made misleading statements and failed to disclose critical information about the company's business and operational efficacy. This included claims that masofaniten, when combined with enzalutamide, provided no clear benefits as compared to enzalutamide alone, significantly affecting treatment expectations for prostate cancer.
Additionally, the lawsuit highlights how the defendants allegedly overstated the prospects of clinical studies. Specifically, the key M-E Combination Study reportedly was unlikely to meet its Phase 2 primary endpoint, further underscoring the misleading statements made to investors.
Next Steps for Investors
A class action lawsuit is already underway. Investors wishing to review the Complaint can access more information on the law firm’s website. It’s crucial for affected investors to act swiftly; those who suffered financial losses due to the challenges faced by ESSA Pharma Inc. have until March 25, 2025, to petition the Court for lead plaintiff status. Being appointed does not affect the ability to partake in potential recovery outcomes.
No Cost Involved for Plaintiffs
Engaging in this class action lawsuit poses no upfront financial risk to the plaintiffs. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only collect fees for their services if they achieve a favorable resolution. This structure aims to ensure that all investors can pursue justice without worrying about immediate legal costs.
About Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman is a prestigious law firm recognized for its commitment to safeguarding investor rights in class actions and shareholder derivative lawsuits. The firm boasts a strong track record, having recovered hundreds of millions of dollars for clients across the nation, demonstrating their dedication and expertise in navigating complex securities matters.
Stay Updated
Investors are encouraged to remain informed by following Bronstein, Gewirtz & Grossman on various social media platforms. Engaging with updates will provide the latest information regarding ongoing legal proceedings and any developments relevant to ESSA Pharma Inc. and other potential securities class actions.
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The lawsuit aims to recover financial damages for investors who acquired ESSA securities during the Class Period and suffered losses due to alleged deceptive practices by the company.
Who can join the class action?
All individuals and entities that purchased or acquired ESSA securities from December 12, 2023, to October 31, 2024, are eligible to join the lawsuit.
What are the costs involved in filing?
There are no upfront costs. The law firm operates on a contingency fee basis, only seeking reimbursement if a recovery is achieved.
How can I stay informed about the lawsuit?
Investors can follow Bronstein, Gewirtz & Grossman on social media platforms for updates regarding the class action and other related news.
What should I do if I want to participate?
Affected investors should take action before the deadline of March 25, 2025, to request lead plaintiff status and ensure their participation in any recovery efforts.
